These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38196182)

  • 1. Cost-effectiveness analysis of cell-based versus egg-based quadrivalent influenza vaccines in the pediatric population in Taiwan.
    Chi CY; Cheng MF; Ko K; Mould JF; Chen CJ; Huang YC; Lee PI
    J Med Virol; 2024 Jan; 96(1):e29279. PubMed ID: 38196182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany.
    Cai R; Gerlier L; Eichner M; Schwehm M; Rajaram S; Mould-Quevedo J; Lamotte M
    J Med Econ; 2021; 24(1):490-501. PubMed ID: 33761803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina.
    Urueña A; Micone P; Magneres MC; McGovern I; Mould-Quevedo J; Sarmento TTR; Giglio N
    Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US.
    Pelton SI; Mould-Quevedo JF; Nguyen VH
    Expert Rev Vaccines; 2024; 23(1):82-87. PubMed ID: 38093415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain.
    Ruiz-Aragón J; Gani R; Márquez S; Alvarez P
    Hum Vaccin Immunother; 2020 Sep; 16(9):2238-2244. PubMed ID: 32040379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season.
    Divino V; Krishnarajah G; Pelton SI; Mould-Quevedo J; Anupindi VR; DeKoven M; Postma MJ
    Vaccine; 2020 Sep; 38(40):6334-6343. PubMed ID: 32739119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate.
    Nham E; Seong H; Hyun H; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Kim E; Choi L; Lee JM; Song JY
    Hum Vaccin Immunother; 2023 Dec; 19(3):2266233. PubMed ID: 37964587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada.
    Nguyen VH; Roy B
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC; Tan EC; Su JJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Epidemiological and Economic Impact of a Cell-Based Quadrivalent Influenza Vaccine in Adults in the US: A Dynamic Modeling Approach.
    Nguyen VH; Hilsky Y; Mould-Quevedo J
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of quadrivalent influenza vaccines in the elderly population of Malaysia.
    Aljunid SM; Mad Tahir NS; Ismail A; Abdul Aziz AF; Azzeri A; Zafirah SA; Aizuddin AN
    Sci Rep; 2023 Oct; 13(1):18771. PubMed ID: 37907537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Children: A Narrative Review.
    Mould-Quevedo JF; Pelton SI; Nguyen VH
    Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
    Jiang M; Li P; Wang W; Zhao M; Atif N; Zhu S; Fang Y
    Vaccine; 2020 Jan; 38(5):1057-1064. PubMed ID: 31787414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population.
    Fochesato A; Sottile S; Pugliese A; Márquez-Peláez S; Toro-Diaz H; Gani R; Alvarez P; Ruiz-Aragón J
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina.
    Urueña A; Micone P; Magneres C; Mould-Quevedo J; Giglio N
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33916048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
    Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.
    Mennini FS; Bini C; Marcellusi A; Rinaldi A; Franco E
    Hum Vaccin Immunother; 2018; 14(8):1867-1873. PubMed ID: 29708843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.
    Bianculli PM; Bellier L; Mangado IO; Pérez CG; Mieres G; Lazarov L; Petitjean A; Dibarboure H; Lopez JG
    Hum Vaccin Immunother; 2022 Nov; 18(5):2050653. PubMed ID: 35344679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.